A Broken Gene Kept Cholesterol Low, but the Pill Took 25 Years
People with the faulty gene had strikingly low cholesterol and far less heart disease, inspiring a new class of drugs.

Invest Like the Best with Patrick O'Shaughnessy · Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500]In 2000, about 3,500 Black and white volunteers in Dallas signed up for a long look at their hearts.
They gave DNA, got scans and imaging, and agreed to be cared for and tracked over time. Researchers were looking for patterns that ordinary checkups miss.
Six years later, they found one. A small group carried a faulty version of a gene called PCSK9, which helps control cholesterol in the blood.
Their LDL, the cholesterol measure doctors watch most closely, sat in the 30s and 40s. That is far below normal.
They also had 85 to 90 percent less heart disease. Zach Reitano, who leads the health company Ro, put it this way: "They were not dying of heart disease."
Daily habits did not seem to change that protection. Smoking, drinking, or rich food still left heart disease unusually rare in this group, though other illnesses could still cause death.
That natural protection pointed to a drug idea: mimic the broken gene and lower cholesterol for everyone else. In 2015, after nearly a decade more work, Amgen introduced Repatha, an injection taken every two weeks.
Later versions stretched to once a month and once every six months. Then, this year, Merck developed an oral drug that does similar work and was approved.
From the start of the Dallas study to that pill took almost a quarter century. Reitano called that span too long, especially for the illness that kills more Americans than any other.
His point was about timing. He argued that a small early nudge might shift a person's path, and asked whether better data and tools could help medicine find such chances sooner.
Questions people ask
What is LDL, and how low is the 30s to 40s?
LDL is often called bad cholesterol because excess amounts can build up in artery walls and lead to heart attacks and strokes. A common target for many adults is below 100, and below 70 for people at high risk, so readings in the 30s and 40s are strikingly low.
What does the PCSK9 gene normally do?
PCSK9 is a gene that helps set how much LDL the liver pulls from the blood. Certain faults in the gene leave less LDL circulating, while drugs that block the PCSK9 protein copy part of that effect and push cholesterol down.
What is Repatha and who takes it?
Repatha is an injected drug that blocks the PCSK9 protein and sharply lowers LDL, usually prescribed when cholesterol remains high despite statins or when patients cannot take them. It is given every two weeks or monthly, and later options extended dosing to longer intervals.
